Loading
Taysha Gene Therapies, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Manning Paul B, was filed 03 Jun 2025.
Insider Decl.
105
Thresholds
n/a
Buy Volume
€25M
22 ops. · all time
Sell Volume
€9M
43 ops. · all time
Who traded when
BuySaleNagendran Sukumar9 sales
Kamran Alam4 sales
Sean P. Nolan2 sales
Manning Paul B1 buy
Since the insiders bought
- +111.1%Entry US$2.79 · Close at T+365 US$5.89
- +19.7%Entry US$1.88 · Close at T+365 US$2.25
- +19.7%Entry US$1.88 · Close at T+365 US$2.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Taysha Gene Therapies, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$13.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.11
Analyst consensus
13 analystsStrong buy
US$9.00Target US$13.00(+216%)US$19.00
Income statement
RevenueUS$9.8M
EBITDA-US$107.8M-1103% margin
Net income-US$109M-1115.3% margin
Valuation
PER (forward)-8.9x
P/Book3.5x
Beta1.17
Balance sheet & cash
Market capUS$1.3B
Total debtUS$70.1M
Free Cash Flow-US$93.8M
Debt / Equity15%
Profitability & ownership
ROE-47.1%
ROA-23.8%
% insiders9.4%
% institutions94.3%
Last declaration on 10 July 2026
Declarations105 total
200,000 shares@ US$6.490.085% mcap39.7% of flowCommonSEC144:0001974158-26-000076
200,000 shares@ US$6.240.082% mcap38.1% of flowCommon StockSEC:0001665124-26-000013:0
19,021 shares@ US$1.710.0019% mcap3.2% of flowCommon StockSEC:0001665124-26-000011:0
200,000 shares@ US$4.460.051% mcap88.2% of flowCommon StockSEC:0001665124-26-000011:1
1,655 shares@ US$4.524.5% of flowCommon StockSEC:0001793412-26-000012:0
26,918 shares@ US$4.611.4% of flowCommon StockSEC:0001665124-26-000008:1
41,312 shares@ US$4.6114.6% of flowCommon StockSEC:0001569926-26-000008:1
23,849 shares@ US$4.6112.6% of flowCommon StockSEC:0001793412-26-000008:1
78,968 shares@ US$4.7543.3% of flowCommon StockSEC:0001793412-26-000008:0
89,132 shares@ US$4.7512.6% of flowCommon StockSEC:0001665124-26-000008:0
136,789 shares@ US$4.75100.0% of flowCommon StockSEC:0001569926-26-000008:0
427,000 shares0Common StockSEC:0001665124-26-000002:3
88,676 shares@ US$1.711.8% of flowCommon StockSEC:0001665124-26-000002:1
200,000 shares@ US$4.7111.2% of flowCommon StockSEC:0001665124-26-000002:2
1,008,000 shares0Common StockSEC:0001569926-26-000002:0
111,324 shares@ US$0.69892.3% of flowCommon StockSEC:0001665124-26-000002:0
359,000 shares0Common StockSEC:0001793412-26-000002:0
39,953 shares@ US$1.710.8% of flowCommon StockSEC:0001665124-25-000003:1
260,047 shares@ US$1.715.3% of flowCommon StockSEC:0001665124-25-000003:3
110,125 shares@ US$4.756.2% of flowCommon StockSEC:0001665124-25-000003:2
260,047 shares@ US$4.5114.0% of flowCommon StockSEC:0001665124-25-000003:4
70,172 shares@ US$0.69891.5% of flowCommon StockSEC:0001665124-25-000003:0
200,000 shares@ US$3.237.6% of flowCommon StockSEC:0001415889-25-024369:1
41,150 shares@ US$0.69890.9% of flowCommon StockSEC:0001415889-25-024369:0
57,054 shares@ US$2.854.9% of flowCommon StockSEC:0001415889-25-022750:0
25 of 105 declarations
About Taysha Gene Therapies, Inc.
On August 16, 2023, 4 insiders at Taysha Gene Therapies, Inc. bought EUR 14,409,349 in total, including EUR 13,627,732 for Paul B. Manning, a director, by far the largest purchase in the record. The same director also bought EUR 3,013,560 on October 31, 2022 and EUR 2,801,519 on June 27, 2024, and has 13 purchases among 16 filings. In all, 22 purchases weigh EUR 24,624,513 (median EUR 215,773) and 43 sales EUR 9,293,425 (median EUR 92,713), or 34% purchases.
The main sales are Sukumar Nagendran's, President and Head of R&D: EUR 1,090,128 on July 10, 2026 and EUR 1,010,917 on December 1, 2025. Sukumar Nagendran (President and Head of R&D) sold EUR 810,412 on January 12, 2026. Kamran Alam, Chief Financial Officer, is the most frequent filer with 22 filings, 14 of them sales.
Read moreShow less
For the 22 purchases tracked at 90 days, the stored median is --44%, with 14% of results positive: recorded past results, not a forecast. The 105 filings, published from September 25, 2020 to July 10, 2026, include 23 grants. This US healthcare company is valued at USD 1.3 billion; over the last twelve months, 22 filings, 12 of them sales and none a purchase.
